Novo Nordisk is reducing the out-of-pocket prices for its weight-loss medication Wegovy and diabetes drug Ozempic for certain consumers.
Current patients who pay for the medications without insurance will now pay $349 per month, down from $499, as announced by the Danish pharmaceutical company on Monday.
New Pricing Structure
For new patients paying out-of-pocket, the cost will be $199 per month for the first two months. After this introductory offer, the monthly price will increase to $349. The $199 offer will be available until March 31, 2026.
This pricing decision comes amid initiatives from the Trump administration aimed at lowering drug prices. Earlier this month, the administration revealed that people covered by Medicare, Medicaid, and the new “TrumpRx” pharmaceutical website would receive discounted pricing for Novo Nordisk’s GLP-1 drugs, along with Eli Lilly’s Zepbound.
Officials stated that these drugs would be priced between $245 to $350 on average, making them more affordable compared to retail prices that can exceed $1,000 per month.
Company’s Statement
Dave Moore, executive vice president of U.S. operations for Novo Nordisk, emphasized the company’s commitment to increasing access to medications for patients with chronic conditions.
Customers can obtain their prescriptions at the new prices through the websites wegovy.com or ozempic.com, at NovoCare Pharmacy, or through selected providers such as Costco.
